Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

VirMedica Makes Capital Investment in D2 Pharma Consulting

By Drug Discovery Trends Editor | February 19, 2015

VirMedica, Inc., a leading provider of technology solutions designed to optimize the commercialization of specialty pharmaceutical products, announced that it has made a significant capital investment in D2 Pharma Consulting, LLC (“D2”).  D2 is an independent consulting firm offering a broad range of commercialization services for manufacturers and service providers in the life sciences industry. 
 
“D2 has a proven track record of excellence in providing a variety of collaborative consulting and advisement services to specialty manufacturers of all sizes,” stated Mark K. Barnes, Chairman and Chief Executive Officer of VirMedica.  “As a technology business, VirMedica will benefit from D2’s in-depth market understanding of the critical challenges facing our mutual customer base.”
 
Based in St. Louis, D2 has advised on a significant number of U.S. pharmaceutical product launches over the last six years including specialty pharmaceutical, traditional pharmaceutical and medical device products.  In addition, D2 works with many organizations including manufacturers, specialty pharmacies and industry solution providers to develop and implement unique operational solutions for specialty pharmaceuticals. While continuing to operate D2 as an autonomous consulting entity, Dean P. Erhardt, President, sees strong strategic value in the new relationship.  “Not only does this transaction secure additional growth capital for D2, but also through our independent consulting engagements, we can deliver valuable insights to VirMedica’s executive team. This insight will significantly elevate the team’s understanding of the ever-changing market dynamics of specialty products.  In turn, our specialty-manufacturing clients will benefit from new technology that is capable of supporting the complex nature of access services for specialty products.”
 
Source: D2

Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE